Dermatologic Therapy · 2020 · 43 citations · 8 references
MedicineClinical SciencesDermatologyClinical EpidemiologyClinical PharmacologyRheumatologyTreatment EffectivenessTreatment Response MonitoringCohort Study InvestigationDisease Severity IndexPrimary Efficacy EndpointsPsoriasis TherapyPsoriatic DiseaseSeverity Index Measurement
High levels of efficacy were demonstrated in randomized controlled trials assessing the efficacy of guselkumab; however, real-life data are lacking. In this retrospective cohort study, we assessed the efficacy and safety of guselkumab in a cohort of psoriasis patients heavily pretreated with biologic agents. Primary efficacy endpoint was the percentage of patients achieving ≥psoriasis area and severity index (PASI) 90 response at week 24. The cohort included 33 patients of mean age 60 ± 13 years. Guselkumab was initiated after a mean of 4.0 ± 1.0 prior biologics failed over a mean period of 7. 4 ± 3.8 years. The mean duration of guselkumab treatment was 9.5 ± 3.7 months; 29 patients completed at least 24 weeks of treatment. At week 24, 22 patients (76%) achieved response of PASI 75 or higher, 18 (62%) achieved PASI 90 or higher, five (17%) PASI 100, and seven (24%) ≤PASI 50. No adverse effects were observed. This study confirms the efficacy and safety of guselkumab in real-world clinical practice, although for a lesser degree compared with clinical trials.
8
Kristian Reich, April W. Armstrong, Peter Foley et al. · Journal of the American Academy of Dermatology · 2017 · 731 citations · Full text
Mark Lebwohl, Arthur Kavanaugh, April W. Armstrong et al. · American Journal of Clinical Dermatology · 2015 · 211 citations · Full text
Patient-relevant treatment goals in psoriasis
Christine Blome, Ramona Gosau, Marc Alexander Radtke et al. · Archives of Dermatological Research · 2015 · 114 citations